Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy: A Phase 2 Study.

Jacqueline A FrenchAndrew J ColeEdward FaughtWilliam H TheodoreAnnamaria VezzaniKore LiowJonathan J HalfordRobert ArmstrongJerzy P SzaflarskiSarah HubbardJagdish PatelKun ChenWei FengMarco RizzoJacob ElkinsGabrielle KnaflerKimberly A Parkersonnull null

Published in: Neurology (2021)

This study provides Class I evidence that IV natalizumab every 4 weeks, compared to placebo, did not significantly change seizure frequency in adults with drug-resistant epilepsy. The study lacked the precision to exclude an important effect of natalizumab.

Keyphrases

drug resistant
multidrug resistant
multiple sclerosis
acinetobacter baumannii
clinical trial
double blind
placebo controlled
preterm birth